Allergy Immunotherapy
Publication Date
March 2024
USD 4.48 billion
USD 7.98 billion
USD 4.86 billion
Allergy Immunotherapy Market by Type (SCIT, SLIT), Allergy Type (Allergic Rhinitis, Asthma, Food Allergy), Distribution Channel - Global Forecast 2024-2030

[191 Pages Report] The Allergy Immunotherapy Market size was estimated at USD 4.48 billion in 2023 and expected to reach USD 4.86 billion in 2024, at a CAGR 8.60% to reach USD 7.98 billion by 2030.

Allergy Immunotherapy Market
To learn more about this report, request a free sample copy
Allergy immunotherapy, known as desensitization or hypo-sensitization, is a medical treatment for allergic reactions to substances such as pollens, house dust mites, molds, and stinging insect venoms. The therapy involves exposing patients to larger and larger amounts of allergens, aiming to change the immune system's response by gradually developing tolerance to these substances. Rising prevalence of allergic diseases, increased awareness and acceptance of immunotherapy as a definitive treatment, advancements in allergy diagnostics, and a growing demand for sublingual immunotherapy (SLIT) due to its convenience and non-invasive nature are the driving factors. However, the high cost of allergen immunotherapy, the risk of adverse reactions associated with allergy shots, inadequate reimbursement policies, and stringent regulatory frameworks that can hinder product approvals and commercialization act as restraining factors. Significant challenges include a lack of patient adherence to long-term treatment regimens, the requirement for personalized treatment strategies imposing logistical complexities, and enhanced efficacy and safety profiles for therapy products. Opportunities abound in exploring novel therapeutic targets and treatment modalities, potential expansion in emerging markets, technological advancements in allergen immunotherapy delivery systems, and developing vaccines with longer-lasting effects. Additionally, partnerships between biotech firms and pharmaceutical giants may fuel further innovation.
Allergy Immunotherapy Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Allergy Immunotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Allergy Immunotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Allergy Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adamis Pharmaceuticals Corporation, ALK-Abelló, Inc., Allergy Therapeutics PLC, ASIT Biotech by DMS Imaging, BioSpace, Inc., Circassia Group PLC, DBV Technologies SA, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., HAL Allergy B.V., HollisterStier Allergy by Jubilant Pharma Company, LETI Pharma, S.L.U., Merck KGaA, Mylan N.V. by Viatris Inc., and Stallergenes Greer International AG.

Market Segmentation & Coverage

This research report categorizes the Allergy Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • SCIT
    • SLIT
  • Allergy Type
    • Allergic Rhinitis
    • Asthma
    • Food Allergy
    • Venom Allergy
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy and Drug Stores

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Allergy Immunotherapy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Allergy Immunotherapy Market?
  3. What are the technology trends and regulatory frameworks in the Allergy Immunotherapy Market?
  4. What is the market share of the leading vendors in the Allergy Immunotherapy Market?
  5. Which modes and strategic moves are suitable for entering the Allergy Immunotherapy Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Allergy Immunotherapy Market, by Type
  7. Allergy Immunotherapy Market, by Allergy Type
  8. Allergy Immunotherapy Market, by Distribution Channel
  9. Americas Allergy Immunotherapy Market
  10. Asia-Pacific Allergy Immunotherapy Market
  11. Europe, Middle East & Africa Allergy Immunotherapy Market
  12. Competitive Landscape
  13. Competitive Portfolio
Companies Mentioned
  • Adamis Pharmaceuticals Corporation
  • ALK-Abelló, Inc.
  • Allergy Therapeutics PLC
  • ASIT Biotech by DMS Imaging
  • BioSpace, Inc.
  • Circassia Group PLC
  • DBV Technologies SA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • HAL Allergy B.V.
  • HollisterStier Allergy by Jubilant Pharma Company
  • LETI Pharma, S.L.U.
  • Merck KGaA
  • Mylan N.V. by Viatris Inc.
  • Stallergenes Greer International AG
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Allergy Immunotherapy Market
The Global Allergy Immunotherapy Market size was estimated at USD 4.48 billion in 2023 and expected to reach USD 4.86 billion in 2024.
The Global Allergy Immunotherapy Market to grow USD 7.98 billion by 2030, at a CAGR of 8.60%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.